Update upon the infection risk in patients receiving TNF alpha inhibitors

References

• Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol. 2009;22(3):557–565.
   PubMed Web of Science ®Google Scholar
• Taylor PC. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol. 2003;3:323–328.
   PubMed Web of Science ®Google Scholar
• Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents–a guide for GPs. Aust Fam Physician. 2007;36:1035–1038.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Cagnati P, et al. Update upon efficacy and safety of TNF-α inhibitors. Expert Opin Drug Saf. 2012;11(1):1–5.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. Autoimmun Rev. 2011;11(1):56–60.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Puppo F. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Drugs Today (Barc). 2011;47(4):277–288.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Barabino G, et al. Anti-tumor necrosis factor-α treatment with infliximab for disseminated granuloma annulare. Am J Clin Dermatol. 2010;11(6):437–439.
   PubMed Web of Science ®Google Scholar
• Puppo F, Murdaca G, Ghio M, et al. Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev. 2005;4(8):537–541.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Puppo F. Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis. Expert Opin Drug Saf. 2013;12(6):801–804.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Puppo F. Long term treatment of rheumatoid arthritis with adalimumab. Open Access Rheumatol. 2013;5:43–49.
   PubMedGoogle Scholar
• Hochberg MC, Lebwohl MG, Plevy SE, et al. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum. 2005;34:819–836.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Contatore M, et al. Potential use of TNF-α inhibitors in systemic sclerosis. Immunotherapy. 2014;6(3):283–289.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Contatore M, et al. Efficacy and safety of etanercept in chronic immune-mediated disease. Expert Opin Drug Saf. 2014;13(5):649–661.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Puppo F. Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. Expert Opin Drug Saf. 2014;13(3):295–305.
   PubMed Web of Science ®Google Scholar
• Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis. 2005;64(Suppl 4):iv2–14.
   PubMedGoogle Scholar
• Gisondi P, Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev. 2007;6:515–519.
   PubMed Web of Science ®Google Scholar
• Kyle S, Chandler D, Griffiths CEM, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology. 2005;44:390–397.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Contini P, et al. Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment. J Interferon Cytokine Res. 2012;32(6):277–279.
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Kerekes G, Soltész P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol. 2009;5(12):677–684.
   PubMed Web of Science ®Google Scholar
• Arenas IA, Armstrong SJ, Xu Y, et al. Chronic tumor necrosis factor-alpha inhibition enhances NO modulation of vascular function in estrogen-deficient rats. Hypertension. 2005;46(1):76–81.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Miglino M, et al. Effects of TNF-α inhibitors upon the mechanisms of action of VEGF. Immunotherapy. 2013;5(2):113–115.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Cagnati P, et al. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis. 2012;224(2):309–317.
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Murdaca G, Colombo BM, et al. Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus. Hum Immunol. 2008;69(8):510–512.
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Colombo BM, Murdaca G, et al. Serum vascular endothelial growth factor and sublingual immunotherapy. Allergy. 2008;63(7):945–946.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Cagnati P, et al. Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors. Redox Rep. 2013;18(3):95–99.
   PubMed Web of Science ®Google Scholar
• Colombo BM, Cacciapaglia F, Puntoni M, et al. Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev. 2009;8(4):309–315.
   PubMed Web of Science ®Google Scholar
• Colombo BM, Murdaca G, Caiti M, et al. Intima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus. Ann N Y Acad Sci. 2007;1108:121–126.
   PubMed Web of Science ®Google Scholar
• Piaserico S, Sandini E, Saldan A, et al. Effects of TNF-alpha inhibitors on circulating Th17 cells in patients affected by severe psoriasis. Drug Dev Res. 2014;75(Suppl 1):S73–6.
   PubMedGoogle Scholar
• Murdaca G, Colombo BM, Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. Intern Emerg Med. 2011;6(6):487–495.
   PubMed Web of Science ®Google Scholar
• Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15:11–34.
   PubMed Web of Science ®Google Scholar
• Lawn SD, Zumla AI. Tuberculosis. Lancet. 2011;378(9785):57–72.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Contatore M, et al. Infection risk associated with anti-TNF-α agents: a review. Expert Opin Drug Saf. 2015;14(4):571–582.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7(3):e012567.
   PubMed Web of Science ®Google Scholar
• Kim H-Y, Lee S-K, Song YW, et al. A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. APLAR J Rheumatol. 2007;10:9–16.
   Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.
   PubMed Web of Science ®Google Scholar
• Cao BL, Qasem A, Sharp RC, et al. Systematic review and meta-analysis on the association of tuberculosis in Crohn’s disease patients treated with tumor necrosis factor-α inhibitors (Anti-TNFα). World J Gastroenterol. 2018;24(25):2764–2775.
   PubMed Web of Science ®Google Scholar
• Cao B, Naser SA. Systematic review and meta-analysis on the risk of tuberculosis in patients with Crohn’s disease who take TNF-α inhibitors. Prospero. 2018.
   Google Scholar
• Winter TA, Wright J, Ghosh S, et al. Intravenous CDP870, a PEGylated Fab’ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to severe Crohn’s disease: an exploratory study. Aliment Pharmacol Ther. 2004;20:1337–1346.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapyfor Crohn’s disease. N Engl J Med. 2010;362:1383–1395.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Hibi T, Lomax KG, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn’s disease. J Crohns Colitis. 2012;6:160–173.
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337:1029–1035.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005;129:807–818.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357:239–250.
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–885.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active Crohn’s disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011;9:670–678.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829–838.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56:1232–1239.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357:228–238.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology. 2012;142:1102–1111.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117:761–769.
   PubMed Web of Science ®Google Scholar
• Regueiro M, Feagan BG, Zou B, et al. Infliximab reduces endoscopic, but not clinical, recurrence of crohn’s disease after ileocolonic resection. Gastroenterology. 2016;150:1568–1578.
   PubMed Web of Science ®Google Scholar
• Regueiro M, El-Hachem S, Kip KE, et al. Postoperative infliximab is not associated with an increase in adverse events in Crohn’s disease. Dig Dis Sci. 2011;56:3610–3615.
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405.
   PubMed Web of Science ®Google Scholar
• UCB Pharma. Corticosteroid sparing effect of certolizumab in Crohn’s disease (COSPAR1) ( NCT00349752; Last Update Posted on September 5, 2014). Available at ClinicalTrials.gov cited 2018 Mar 27
   Google Scholar
• Lémann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology. 2006;130:1054–1061.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–333.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.
   PubMed Web of Science ®Google Scholar
• D’haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: A European multicenter trial. Gastroenterology. 1999;116:1029–1034.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 76(6):1101–1136.
   PubMed Web of Science ®Google Scholar
• Chiu YM, Lang HC, Lin HY, et al. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan. Int J Rheum Dis. 2014;17(Suppl 3):9–19.
   PubMedGoogle Scholar
• Ke WM, Chen LS, Parng IM, et al. Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan. Int J Tuberc Lung Dis. 2013;17:1590–1595.
   PubMed Web of Science ®Google Scholar
• Baddley JW, Winthrop KL, Chen L, et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study. Ann Rheum Dis. 2014;73:1942–1948.
   PubMed Web of Science ®Google Scholar
• Tam LS, Leung CC, Ying SK, et al. Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong—the role of TNF blockers in an area of high tuberculosis burden. Clin Exp Rheumatol. 2010;28:679–685.
   PubMedGoogle Scholar
• Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum. 2009;60:1884–1894.
   PubMed Web of Science ®Google Scholar
• Liao H, Zhong Z, Liu Z, et al. Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. Int J Rheum Dis. 2017;20(2):161–168.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69(3):522–528.
   PubMed Web of Science ®Google Scholar
• Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15(sup1):11–34.
   PubMed Web of Science ®Google Scholar
• Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48:1667–1675.
   PubMed Web of Science ®Google Scholar
• Iannone F, Cantini F, Lapadula G. Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations. J Rheumatol Suppl. 2014;91:41–46.
   PubMedGoogle Scholar
• Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64:625–639.
   PubMed Web of Science ®Google Scholar
• Koike R, Takeuchi T, Eguchi K, et al. Japan college of rheumatology. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17:451–458.
   PubMedGoogle Scholar
• Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46:1563–1576.
   PubMed Web of Science ®Google Scholar
• Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010;36:1185–1206.
   PubMed Web of Science ®Google Scholar
• Theis VS, Rhodes JM. Minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:19–30.
   PubMed Web of Science ®Google Scholar
• British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax. 2005;60:800–805.
   PubMed Web of Science ®Google Scholar
• Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun. 1988;56(10):2563–2569.
   PubMed Web of Science ®Google Scholar
• Bowie VL, Snella KA, Gopalachar AS, et al. Listeria meningitis associated with infliximab. Ann Pharmacother. 2004;38(1):58–61.
   PubMed Web of Science ®Google Scholar
• Izbeki F, Nagy F, Szepes Z, et al. Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn’s disease. Inflamm Bowel Dis. 2008;14(3):429–431.
   PubMed Web of Science ®Google Scholar
• Kesteman T, Yombi JC, Gigi J, et al. Listeria infections associated with infliximab: case reports. Clin Rheumatol. 2007;26(12):2173–2175.
   PubMed Web of Science ®Google Scholar
• Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003;48(2):319–324.
   PubMed Web of Science ®Google Scholar
• Tweezer-Zaks N, Shiloach E, Spivak A, et al. Listeria monocytogenes sepsis in patients treated with anti-tumor necrosis factor-alpha. Isr Med Assoc J. 2003;5(11):829–830.
   PubMed Web of Science ®Google Scholar
• Abreu C, Magro F, Vilas-Boas F, et al. Listeria infection in patients on anti-TNF treatment: report of two cases and review of the literature. J Crohns Colitis. 2013;7(2):175–182.
   PubMed Web of Science ®Google Scholar
• Schaible TF Important drug warning (Centocor). FDA Web site. October 4, 2001. 2012. 10-1-2012. Ref Type: Internet Communication; October 4, 2001.
   Google Scholar
• Morelli J, Wilson FA. Does administration of infliximab increase susceptibility to listeriosis?. Am J Gastroenterol. 2000;95(3):841–842.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54(8):2368–2376.
   PubMed Web of Science ®Google Scholar
• Ramos JM, García-Sepulcre MF, Masiá M, et al. Listeria monocytogenes infection in patients with inflammatory bowel diseases receiving anti-tumor necrosis factor therapy. Rev Esp Enferm Dig. 2010;102(10):614–616.
   PubMed Web of Science ®Google Scholar
• Kamath BM, Mamula P, Baldassano RN, et al. Listeria meningitis after treatment with infliximab. J Pediatr Gastroenterol Nutr. 2002;34:410–412.
   PubMed Web of Science ®Google Scholar
• Joosten AA, van Olffen GH, Hageman G. Meningitis due to Listeria monocytogenes as a complication of infliximab therapy. Ned Tijdschr Geneeskd. 2003;147:1470–1472.
   PubMedGoogle Scholar
• Tweezer-Zaks N, Shiloach E, Spivak A, et al. Listeria monocytogenes sepsis in patients treated with anti-tumor necrosis factor-alpha. Isr Med Assoc J. 2003;5:829–830.
   PubMed Web of Science ®Google Scholar
• de la Fuente Penco B, Marcó Piella A, Riera Mestre A, et al. Sepsis caused by Listeria monocytogenes related with the use of infliximab. Med Clin (Barc). 2005;124:398.
   PubMed Web of Science ®Google Scholar
• Williams G, Khan AA, Schweiger F. Listeria meningitis complicating infliximab treatment for Crohn’s disease. Can J Infect Dis Med Microbiol. 2005;16:289–292.
   PubMedGoogle Scholar
• Dederichs F, Pinciu F, Gerhard H, et al. Listeria meningitis in a patient with Crohn’s disease–a seldom, but clinically relevant adverse event of therapy with infliximab. Z Gastroenterol. 2006;44:657–660.
   PubMed Web of Science ®Google Scholar
• Osuna Molina R, Ferrer Ríos T, Gallego Gallegos R, et al. Listeria meningitis as complication of treatment with infliximab in a patient with Crohn’s disease. Rev Esp Enferm Dig. 2006;98:60–61.
   PubMed Web of Science ®Google Scholar
• Ramanampamonjy RM, Laharie D, Bonnefoy B, et al. Infliximab therapy in Crohn’s disease complicated by Listeria monocytogenes meningoencephalitis. Gastroenterol Clin Biol. 2006;30:157–158.
   PubMed Web of Science ®Google Scholar
• Izbéki F, Nagy F, Szepes Z, et al. Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn’s disease. Inflamm Bowel Dis. 2008;14:429–431.
   PubMed Web of Science ®Google Scholar
• Aparicio AG, Munoz-Fernandez S, Bonilla G, et al. Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: comment on the letter by Gluck et al. Arthritis Rheum. 2003;48(6):1764–1765.
   PubMed Web of Science ®Google Scholar
• Glück T, Linde HJ, Schölmerich J, et al. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum. 2002;46(8):2255–2257.
   PubMed Web of Science ®Google Scholar
• Bodro M, Paterson DL. Listeriosis in patients receiving biologic therapies. Eur J Clin Microbiol Infect Dis. 2013;32(9):1225–1230.
   PubMed Web of Science ®Google Scholar
• Kuehn BM. Growing list of infections linked to TNF blockers. JAMA. 2011;306(13):1430.
   PubMed Web of Science ®Google Scholar
• Rachapalli S, O’Daunt S. Septic arthritis due to Listeria monocytogenes in a patient receiving etanercept. Arthritis Rheum. 2005;52(3):987.
   PubMedGoogle Scholar
• Schett G, Herak P, Graninger W, et al. Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature. J Clin Microbiol. 2005;43(5):2537–2541.
   PubMed Web of Science ®Google Scholar
• Pagliano P, Attanasio V, Fusco U, et al. Does etanercept monotherapy enhance the risk of Listeria monocytogenes meningitis?. Ann Rheum Dis. 2004;63(4):462–463.
   PubMed Web of Science ®Google Scholar
• Abreu C, Sarmento A, Magro F. Screening, prophylaxis and counselling before the start of biological therapies: A practical approach focused on IBD patients. Dig Liver Dis. 2017;49(12):1289–1297.
   PubMedGoogle Scholar
• Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76(7):1253–1262.
   PubMed Web of Science ®Google Scholar
• Nath A, Berger JR. Complications of immunosuppressive/immunomodulatory therapy in neurological diseases. Curr Treat Options Neurol. 2012;14:241–255.
   PubMed Web of Science ®Google Scholar
• Rudol M, Scherer S. High incidence of Listeria monocytogenes in European red smear cheese. Int J Food Microbiol. 2001;63:91–98.
   PubMed Web of Science ®Google Scholar
• Davies R, Dixon WG, Watson KD, et al. Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK. Ann Rheum Dis. 2013;72(3):461–462.
   PubMed Web of Science ®Google Scholar
• Russian DA, Levine SJ. Pneumocystis carinii pneumonia in patients without HIV infection. Am J Med Sci. 2001;321(1):56–65.
   PubMed Web of Science ®Google Scholar
• Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350(24):2487–2498.
   PubMed Web of Science ®Google Scholar
• Cheng CY, Chen MY, Hsieh SM, et al. Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy. BMC Infect Dis. 2010;10:126–133.
   PubMed Web of Science ®Google Scholar
• Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis. 2002;34:1098–1107.
   PubMed Web of Science ®Google Scholar
• Ogawa J, Harigai M, Nagasaka K, et al. Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy. Mod Rheumatol. 2005;15:91–96.
   PubMedGoogle Scholar
• Grubbs JA, Baddley JW. Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis. Curr Rheumatol Rep. 2014;16(10):445.
   PubMed Web of Science ®Google Scholar
• Arnold TM, Sears CR, Hage CA. Invasive fungal infections in the era of biologics. Clin Chest Med. 2009;30(2):279–286.
   PubMed Web of Science ®Google Scholar
• Tokuda H, Sakai F, Yamada H, et al. Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. Intern Med. 2008;47(10):915–923.
   PubMed Web of Science ®Google Scholar
• Mori S, Imamura F, Kiyofuji C, et al. Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor α neutralizing antibody. Mod Rheumatol. 2006;16:58–62.
   PubMedGoogle Scholar
• Seddik M, Melliez H, Seguy D, et al. Pneumocystis jiroveci (carinii) pneumonia after initiation of infliximab and azathioprine therapy in a patient with Crohn’s disease. Inflamm Bowel Dis. 2005;11:618–620.
   PubMed Web of Science ®Google Scholar
• Tai TL, O’Rourke KP, McWeeney M, et al. Pneumocystis carinii pneumonia following a second infusion of infliximab [letter]. Rheumatology (Oxford). 2002;41:951–952.
   PubMed Web of Science ®Google Scholar
• Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-α therapy with infliximab for Crohn’s disease. Inflamm Bowel Dis. 2004;10:657–660.
   PubMed Web of Science ®Google Scholar
• Komano Y, Harigai M, Koike R, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009;61(3):305–312.
   PubMed Web of Science ®Google Scholar
• Lawrance IC, Radford-Smith GL, Bampton PA, et al. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol. 2010;25:1732–1738.
   PubMed Web of Science ®Google Scholar
• Mori S, Tomita Y, Horikawa T, et al. Delayed spinal infection after laminectomy in a patient with rheumatoid arthritis interruptedly exposed to anti-tumor necrosis factor alpha agents. Clin Rheumatol. 2008;27(7):937–939.
   PubMed Web of Science ®Google Scholar
• Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci. 2007;52:1481–1484.
   PubMed Web of Science ®Google Scholar
• Desales AL, Mendez-Navarro J, Méndez-Tovar LJ, et al. Pneumocystosis in a patient with Crohn’s disease treated with combination therapy with adalimumab. J Crohns Colitis. 2012;6(4):483–487.
   PubMed Web of Science ®Google Scholar
• Ikeuchi H, Umemoto A, Tsukida M, et al. Pneumocystis pneumonia developed in two patients with rheumatoid arthritis during treatment of adalimumab. Nihon Rinsho Meneki Gakkai Kaishi. 2011;34(5):420–425.
   PubMedGoogle Scholar
• Colombel JF, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohn’s disease. Inflamm Bowel Dis. 2009;15:1308–1319.
   PubMed Web of Science ®Google Scholar
• Bruce ES, Kearsley-Fleet L, Watson KD, et al. Risk of pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: results from the British society for rheumatology biologics register for rheumatoid arthritis. Rheumatology (Oxford). 2016;55(7):1336–1337.
   PubMed Web of Science ®Google Scholar
• Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–35.
   PubMed Web of Science ®Google Scholar
• Zhou P, Miller G, Seder RA. Factors involved in regulating primary and secondary immunity to infection with Histoplasma capsulatum: TNF-alpha plays a critical role in maintaining secondary immunity in the absence of IFNgamma. J Immunol. 1998;160(3):1359–1368.
   PubMed Web of Science ®Google Scholar
• Allendoerfer R, Deepe GS Jr. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J Immunol. 1998;160(12):6072–6082.
   PubMed Web of Science ®Google Scholar
• Allendoerfer R, Deepe GS Jr. Regulation of infection with Histoplasma capsulatum by TNFR1 and −2. J Immunol. 2000;165(5):2657–2664.
   PubMed Web of Science ®Google Scholar
• Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. Am J Med. 2002;112(1):78.
   PubMed Web of Science ®Google Scholar
• Wood KL, Hage CA, Knox KS, et al. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med. 2003;167(9):1279–1282.
   PubMed Web of Science ®Google Scholar
• Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565–2570.
   PubMed Web of Science ®Google Scholar
• Wheat LJ, Smith EJ, Sathapatayavongs B, et al. Histoplasmosis in renal allograft recipients. Two large urban outbreaks. Arch Intern Med. 1983;143(4):703–707.
   PubMed Web of Science ®Google Scholar
• Peddi VR, Hariharan S, First MR. Disseminated histoplasmosis in renal allograft recipients. Clin Transplant. 1996;10(2):160–165.
   PubMed Web of Science ®Google Scholar
• Vail GM, Young RS, Wheat LJ, et al. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl Infect Dis. 2002;4(3):148–151.
   PubMedGoogle Scholar
• Dotson JL, Crandall W, Mousa H, et al. Presentation and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with antitumor necrosis factor alpha therapy: a case series. Inflamm Bowel Dis. 2011;17(1):56–61.
   PubMed Web of Science ®Google Scholar
• Lan N, Patil DT, Shen B. Histoplasma capsulatum infection in refractory Crohn’s disease of the pouch on anti-TNF biological therapy. Am J Gastroenterol. 2013;108(2):281–283.
   PubMed Web of Science ®Google Scholar
• Lim LT, Ruzmetova N, Ballinger SH, et al. Acute pulmonary histoplasmosis in a patient with uveitis after infliximab therapy. Int Ophthalmol. 2011;31(4):349–351.
   PubMedGoogle Scholar
• Hage CA, Bowyer S, Tarvin SE, et al. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis. 2010;50(1):85–92.
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261–1265.
   PubMed Web of Science ®Google Scholar
• Muñoz-Oca JE, Villarreal Morales ML, Nieves-Rodriguez A, et al. Concomitant disseminated histoplasmosis and disseminated tuberculosis after tumor necrosis factor inhibitor treatment: a case report. BMC Infect Dis. 2017;17(1):70.
   PubMedGoogle Scholar
• Agudelo CA, Restrepo CA, Molina DA, et al. Tuberculosis and histoplasmosis co-infection in AIDS patients. Am J Trop Med Hyg. 2012;87:1094–1098.
   PubMed Web of Science ®Google Scholar
• Vallabhaneni S, Chiller TM. Fungal infections and new biologic therapies. Curr Rheumatol Rep. 2016;18(5):29.
   PubMed Web of Science ®Google Scholar
• Vergidis P, Avery RK, Wheat LJ, et al. Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases. Clin Infect Dis. 2015;61(3):409–417.
   PubMed Web of Science ®Google Scholar
• Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the infectious diseases society of America. Clin Infect Dis. 2007;45(7):807–825.
   PubMed Web of Science ®Google Scholar
• Kasahara S, Ando K, Saito K, et al. Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J Virol. 2003;77(4):2469–2476.
   PubMed Web of Science ®Google Scholar
• Charpin C, Guis S, Colson P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther. 2009;11(6):R179.
   PubMed Web of Science ®Google Scholar
• Ballanti E, Conigliaro P, Chimenti MS, et al. Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients. Drug Dev Res. 2014;75(Suppl 1):S42–5.
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, Atteno M, et al. Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol. 2014;33(2):273–276.
   PubMed Web of Science ®Google Scholar
• Iannone F, La Montagna G, Bagnato G, et al. Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial. J Rheumatol. 2014;41(2):286–292.
   PubMed Web of Science ®Google Scholar
• Caporali R, Bobbio-Pallavicini F, Atzeni F, et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/antihepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken). 2010;62:749–754.
   PubMed Web of Science ®Google Scholar
• Tamori A, Koike T, Goto H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol. 2011;46:556–564.
   PubMed Web of Science ®Google Scholar
• Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol. 2011.
   Web of Science ®Google Scholar
• Papalopoulos I, Fanouriakis A, Kougkas N, et al. Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study. Clin Exp Rheumatol. 2018;36(1):102–109.
   PubMed Web of Science ®Google Scholar
• Chiu YM, Lai MS, Chan KA. Assessing risk of liver enzyme elevation in patients with immune-mediated diseases and different hepatitis B virus serostatus receiving anti-TNF agents: a nested case-control study. Arthritis Res Ther. 2017;19(1):214.
   PubMedGoogle Scholar
• Barone M, Notarnicola A, Lopalco G, et al. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology. 2015;62(1):40–46.
   PubMed Web of Science ®Google Scholar
• Koutsianas C, Thomas K, Vassilopoulos D. Hepatitis B reactivation in rheumatic diseases: screening and prevention. Rheum Dis Clin North Am. 2017;43:133–149.
   PubMed Web of Science ®Google Scholar
• Shah R, Ho EY, Kramer JR, et al. Hepatitis B virus screening and reactivation in a national VA cohort of patients with inflammatory bowel disease treated with tumor necrosis factor antagonists. Dig Dis Sci. 2018;63(6):1551–1557.
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–185.
   PubMed Web of Science ®Google Scholar
• Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010;29(9):1021–1029.
   PubMed Web of Science ®Google Scholar
• Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519–528.
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662.
   PubMed Web of Science ®Google Scholar
• Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol. 2011;17(12):1531–1537.
   PubMed Web of Science ®Google Scholar
• Baddley JW, Cantini F, Goletti D, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clin Microbiol Infect. 2018;24(Suppl 2):S10–S20.
   PubMed Web of Science ®Google Scholar
• Harigai M, Mochida S, Mimura T, et al. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. Mod Rheumatol. 2014;24(1):1–7.
   PubMed Web of Science ®Google Scholar
• Zein NN, Etanercept Study G. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005;42:315–322.
   PubMed Web of Science ®Google Scholar
• Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol. 2004;31:107–109.
   PubMed Web of Science ®Google Scholar
• Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol. 2004;51:580–584.
   PubMed Web of Science ®Google Scholar
• Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum. 2004;51:800–804.
   PubMed Web of Science ®Google Scholar
• Peterson JR, Hsu FC, Simkin PA, et al. Effect of tumour necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis. 2003;62:1078–1082.
   PubMed Web of Science ®Google Scholar
• Burton MJ, Curtis JR, Yang S, et al. Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis C virus infection. J Rheumatol. 2017;565–570.
   PubMed Web of Science ®Google Scholar
• Brunasso AM, Puntoni M, Gulia A, et al. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford). 2011;50:1700–1711.
   PubMed Web of Science ®Google Scholar
• Smith CH, Anstey AV, Barker JN, et al. British association of dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161:987–1019.
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–850.
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Samonis G, Boumpas DT, et al. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc. 2008;83:181–194.
   PubMed Web of Science ®Google Scholar
• Braun J, Brandt J, Listing J, et al. Treatment of active in ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet. 2002;359:1187–1193.
   PubMed Web of Science ®Google Scholar
• Guedes-Barbosa LS, Da Costa IP, Fernandes V, et al. Leishmaniasis during anti-tumor necrosis factor therapy: report of 4 cases and review of the literature (additional 28 cases]. Semin Arthritis Rheum. 2013;43:152–157.
   PubMed Web of Science ®Google Scholar
• Aikawa NE, Rosa DT, Del Negro GM, et al. Systemic and localized infection by Candida species in patients with rheumatic diseases receiving anti-TNF therapy. Rev Bras Reumatol Engl Ed. 2016;56(6):478–482.
   PubMedGoogle Scholar
• Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum. 2004;50:1959–1966.
   PubMed Web of Science ®Google Scholar
• Choi K, Deval N, Vyas A, et al. The utility of screening for coccidioidomycosis in recipients of inhibitors of tumor necrosis factor-α. Clin Infect Dis. in press;2018.
   Google Scholar
• Bello SL, Serafino L, Bonali C, et al. Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents. Reumatismo. 2012;64(5):299–306.
   PubMedGoogle Scholar
• Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309:887–895.
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA. 2009;301:737–744.
   PubMed Web of Science ®Google Scholar
• Galloway JB, Mercer LK, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British society for rheumatology biologics register. Ann Rheum Dis. 2013;72:229–234.
   PubMed Web of Science ®Google Scholar
• Serac G, Tubach F, Mariette X, et al. Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry. J Invest Dermatol. 2012;132:726–729.
   PubMed Web of Science ®Google Scholar
• Garcia-Doval I, Perez-Zafrilla B, Descalzo MA, et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis. 2010;69:1751–1755.
   PubMed Web of Science ®Google Scholar
• Novosad SA, Winthrop KL. Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae. Clin Infect Dis. 2014;58:1587e98.
   Web of Science ®Google Scholar
• Germano V, Cattaruzza MS, Osborn J, et al. Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists. J Transl Med. 2014;12:77.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Orsi A, Spanò F, et al. Vaccine-preventable infections in Systemic Lupus Erythematosus. Hum Vaccin Immunother. 2016;12(3):632–643.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Orsi A, Spanò F, et al. Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current views upon safety and immunogenicity. Autoimmun Rev. 2014;13(2):75–84.
   PubMed Web of Science ®Google Scholar
• Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309–318.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1–26.
   PubMed Web of Science ®Google Scholar
• Ma C, Walters B, Fedorak RN. Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn’s disease. World J Gastroenterol. 2013;19(21):3347–3351.
   PubMed Web of Science ®Google Scholar
• Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J. 2004;23(2):132–137.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Gulli R, Spanò F, et al. TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis. J Invest Dermatol. 2014;134(10):2503–2509.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Contatore M, et al. Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy. Expert Opin Drug Metab Toxicol. 2014;10(12):1703–1710.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Gulli R, Spanò F, et al. Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept? Drug Dev Res. 2014;75(Suppl 1):S7–S10.
   PubMed Web of Science ®Google Scholar